Axon Enterprise, Inc $AXON Shares Sold by Defender Capital LLC.

Key Points

• Defender Capital LLC reduced its stake in Axon Enterprise, Inc by 3.1% in the second quarter, owning 40,224 shares valued at approximately $33.3 million, which represents 11.3% of its portfolio.
• Insider activity included CEO Patrick W. Smith selling 10,000 shares for over $8.3 million, while Director Hadi Partovi bought 1,358 shares at a cost of about $1 million.
• Axon reported a strong quarterly earnings performance with earnings per share of $2.12, exceeding analysts' expectations, and a revenue increase of 32.6% year-over-year, reaching $668.54 million.

Defender Capital LLC. reduced its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,224 shares of the biotechnology company's stock after selling 1,305 shares during the quarter. Axon Enterprise comprises approximately 11.3% of Defender Capital LLC.'s investment portfolio, making the stock its 3rd largest position. Defender Capital LLC. owned about 0.05% of Axon Enterprise worth $33,303,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. NorthRock Partners LLC raised its stake in Axon Enterprise by 30.6% in the 2nd quarter. NorthRock Partners LLC now owns 1,204 shares of the biotechnology company's stock valued at $997,000 after purchasing an additional 282 shares during the last quarter. Atria Wealth Solutions Inc. grew its holdings in Axon Enterprise by 3.8% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 2,168 shares of the biotechnology company's stock valued at $1,794,000 after buying an additional 80 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Axon Enterprise by 17.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,877 shares of the biotechnology company's stock valued at $3,210,000 after buying an additional 571 shares in the last quarter. Total Clarity Wealth Management Inc. grew its holdings in Axon Enterprise by 22.2% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 1,255 shares of the biotechnology company's stock valued at $1,039,000 after buying an additional 228 shares in the last quarter. Finally, Yousif Capital Management LLC grew its holdings in Axon Enterprise by 1.1% in the 2nd quarter. Yousif Capital Management LLC now owns 10,066 shares of the biotechnology company's stock valued at $8,334,000 after buying an additional 105 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the transaction, the chief executive officer owned 3,053,982 shares of the company's stock, valued at approximately $2,538,744,696.78. This represents a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hadi Partovi bought 1,358 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average cost of $740.00 per share, for a total transaction of $1,004,920.00. Following the purchase, the director owned 237,938 shares in the company, valued at $176,074,120. This represents a 0.57% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 59,932 shares of company stock worth $45,115,616. Insiders own 5.70% of the company's stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $710.00 on Tuesday. The stock has a market cap of $55.74 billion, a PE ratio of 175.31, a P/E/G ratio of 27.30 and a beta of 1.41. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a twelve month low of $422.38 and a twelve month high of $885.91. The stock has a fifty day simple moving average of $754.87 and a 200-day simple moving average of $716.06.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company's revenue was up 32.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Ratings Changes

AXON has been the subject of several analyst reports. Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price for the company in a report on Tuesday, August 5th. Piper Sandler initiated coverage on Axon Enterprise in a report on Tuesday, September 23rd. They issued an "overweight" rating and a $893.00 target price for the company. Northland Securities set a $800.00 target price on Axon Enterprise in a report on Tuesday, August 5th. Zacks Research cut Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an "overweight" rating in a report on Friday, July 11th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.